Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Hematology

Background:

• Clinical decisions to reverse P2Y12 inhibitor antiplatelet effects arise from balancing ischemic and bleeding risks.
• Emergency situations like severe bleeding, high-risk procedures, or major trauma necessitate reversing antiplatelet therapy.
• P2Y12 inhibitors are crucial in preventing thrombotic events but pose bleeding risks.

Purpose of the Study:

• To review current strategies for reversing the antiplatelet effects of P2Y12 receptor inhibitors.
• To evaluate the efficacy of platelet concentrate supplementation and novel agents in reversing these effects.
• To highlight the challenges and advancements in managing bleeding complications in patients on antiplatelet therapy.

Main Methods:

• Review of ex vivo and in vivo studies on platelet supplementation for reversing antiplatelet effects.
• Analysis of studies investigating platelet transfusion efficacy in patients on clopidogrel, prasugrel, and ticagrelor.
• Examination of experimental data on serum albumin and clinical data on a novel monoclonal antibody fragment (PB2452).

Main Results:

• Platelet concentrates can reverse the effects of clopidogrel and prasugrel, with greater efficacy for prasugrel if transfused >6 hours post-dose.
• Results regarding platelet concentrate efficacy in reversing ticagrelor are conflicting.
• PB2452 demonstrated rapid (within 5 minutes) and sustained (20-24 hours) reversal of ticagrelor's antiplatelet effect in a first-in-human study.

Conclusions:

• Platelet supplementation is a viable option for reversing thienopyridine (clopidogrel, prasugrel) inhibition, with timing considerations.
• Reversal of ticagrelor remains a clinical challenge, with current methods yielding inconsistent results.
• PB2452 represents a significant advancement, offering a highly effective method for rapid and sustained ticagrelor reversal.